Aprea Therapeutics Pursues Precision Oncology with ATRN-119 and APR-1051 Trials

Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received FDA clearance of its IND. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 supported by a Phase II SBIR grant from the National Cancer Institute.